Publications by authors named "Marc Eid"

Article Synopsis
  • The study focuses on the effectiveness and safety of second-line treatment options (docetaxel vs. alternative ARSI) for patients aged 75 and older who have metastatic castration-resistant prostate cancer (mCRPC) after failing first-line androgen receptor signaling inhibitors (ARSIs).
  • Researchers analyzed a group of 122 elderly patients, finding no significant differences in overall survival or progression-free survival when comparing those who received docetaxel to those who received an alternative ARSI.
  • The results suggest that both treatment options are similar for elderly patients, providing useful insights despite the limitations of a small and retrospective study design.
View Article and Find Full Text PDF
Article Synopsis
  • Managing metastatic castration-resistant prostate cancer (mCRPC) in men aged 75 and older is difficult due to limited research, but common first-line treatments include abiraterone acetate plus prednisone (AA) and enzalutamide (Enza).
  • A study analyzed 337 patients aged 75+ who started AA or Enza and found no significant differences in survival rates or adverse effects between those who previously used docetaxel (D) and those who only received androgen deprivation therapy (ADT).
  • The results imply that elderly men with mCRPC can expect similar outcomes and side effect profiles from AA or Enza, irrespective of prior D treatment, though the study's retrospective nature
View Article and Find Full Text PDF
Article Synopsis
  • The commentary discusses an article by Correa et al that investigates how circulating tumor DNA can be linked to the prognosis of patients with renal cell carcinoma.
  • It highlights the importance of using circulating tumor DNA as a potential biomarker to predict patient outcomes in this type of cancer.
  • The findings suggest that monitoring circulating tumor DNA levels may help improve treatment strategies and patient management in renal cell carcinoma.
View Article and Find Full Text PDF
Article Synopsis
  • * Methods: Researchers analyzed data from 94 patients treated at 29 institutions, assessing various factors like type of therapy, timing of recurrence, and patient risk categories, while also monitoring treatment-related side effects.
  • * Key Findings: The study revealed an 18-month PFS rate of 45% and overall survival (OS) rate of 85%, with common treatment-related side effects including skin toxicity and fatigue; it did have limitations due to patient selection.
View Article and Find Full Text PDF

Purpose: Histologic transformation to small cell lung cancer (SCLC) is a mechanism of treatment resistance in patients with advanced oncogene-driven lung adenocarcinoma (LUAD) that currently requires histologic review for diagnosis. Herein, we sought to develop an epigenomic cell-free DNA (cfDNA)-based approach to noninvasively detect small cell transformation in patients with EGFR mutant (EGFRm) LUAD.

Experimental Design: To characterize the epigenomic landscape of transformed (t)SCLC relative to LUAD and de novo SCLC, we performed chromatin immunoprecipitation sequencing (ChIP-seq) to profile the histone modifications H3K27ac, H3K4me3, and H3K27me3; methylated DNA immunoprecipitation sequencing (MeDIP-seq); assay for transposase-accessible chromatin sequencing; and RNA sequencing on 26 lung cancer patient-derived xenograft (PDX) tumors.

View Article and Find Full Text PDF

The management of renal cell carcinoma (RCC) has advanced significantly in the past two decades. Many promising functional imaging modalities such as radiolabeled tracer targeting carbonic anhydrase IX and prostate-specific membrane antigen are under development to detect primary kidney tumors, stage systemic disease, and assess treatment response in RCC. Immune checkpoint inhibitors targeting PD-1 and cytotoxic T-cell lymphocyte-4 have changed the treatment paradigm in advanced RCC.

View Article and Find Full Text PDF

Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor survival and a heightened response to immune checkpoint inhibitors (ICIs). Two major barriers to improving outcomes for sRCC are the limited understanding of its gene regulatory programs and the low diagnostic yield of tumor biopsies due to spatial heterogeneity. Herein, we characterized the epigenomic landscape of sRCC by profiling 107 epigenomic libraries from tissue and plasma samples from 50 patients with RCC and healthy volunteers.

View Article and Find Full Text PDF

Background: Current tobacco smoking is independently associated with decreased overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC) treated with targeted monotherapy (VEGF-TKI). Herein, we assess the influence of smoking status on the outcomes of patients with mRCC treated with the current first-line standard of care of immune checkpoint inhibitor (ICI)-based regimens.

Materials And Methods: Real-world data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) were collected retrospectively.

View Article and Find Full Text PDF

Patients with metastatic clear cell renal cell carcinoma (mccRCC) experience highly heterogeneous outcomes when treated with standard-of-care systemic regimens. Therefore, valid biomarkers are needed to predict the clinical response to these therapies and help guide management. In this review, the authors outline relevant and promising biomarkers for patients with mccRCC receiving systemic therapies, with a focus on immunotherapy-based regimens.

View Article and Find Full Text PDF